{"disease":{"id":"advanced-breast-carcinoma","name":"advanced breast carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT02115282","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":608,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06243432","title":"Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06016738","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05295043","title":"Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05173103","title":"Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT03941756","title":"Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT04715958","title":"SHAPE Neoadjuvant Chemotherapy Response","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Kibo Nam","has_results":false},{"nct_id":"NCT06507930","title":"The COMPASSION Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03809988","title":"PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03251378","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":true},{"nct_id":"NCT04682431","title":"A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05945290","title":"Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT07460752","title":"Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06799065","title":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Accent Therapeutics","has_results":false},{"nct_id":"NCT04691375","title":"A Study of PY314 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":86,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT02849496","title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05656131","title":"Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":80,"lead_sponsor_name":"wang shusen","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT01149083","title":"Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT00576654","title":"Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03281902","title":"Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03285568","title":"Patterns of Prescribing and Monitoring of Palbociclib","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT03129139","title":"A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Minneamrita Therapeutics LLC","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT03707574","title":"Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04090567","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06179303","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Washington","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}